Blood Res.  2019 Sep;54(3):236-240. 10.5045/br.2019.54.3.236.

Successful treatment of non-IgM lymphoplasmacytic lymphoma by bortezomib-containing regimen: case reports and review of literature

• Ito K
• Nishiyama
• Hirano K
• Yamada K
• Sekiguchi

• KMID: 2459392
• DOI: http://doi.org/10.5045/br.2019.54.3.236

Abstract

No abstract available.

MeSH Terms

Lymphoma*

Figure

• 

  Fig. 1 Computed tomography at diagnosis. (A) A soft tissue mass in the mesenteric lymph nodes in Case 1. (B) A bulky mass in the mediastinum in Case 2.

• 

  Fig. 2 (A–C) Neoplastic cells in the bone marrow in Case 1. (A) Hematoxylin and eosin staining: diffused invasion of the neoplastic cells was observed in the bone marrow biopsy specimen (original magnification ×400). (B) Staining with CD138: The cytoplasm of the neoplastic lymphoplasmacytes and plasmacytes was strongly positive for CD138 (×400). (C) Staining with CD20: The cytoplasm of the neoplastic small lymphocytes and lymphoplasmacytic cells were strongly positive for CD20 (×630). (D–F) The neoplastic cells of the mediastinum tumor mass in Case 2. (D) Hematoxylin and eosin staining: Neoplastic lymphocytes, lymphoplasmacytes, and plasmacytes were noted in the mediastinum tumor specimen (×400). (E) Staining with CD20: The cytoplasm of the neoplastic lymphocytes was strongly positive for CD20 (×400). (F) Staining with CD138: The cytoplasm of the neoplastic lymphoplasmacytes and plasmacytes was strongly positive for CD138 (×400).

Reference

1. Swerdlow SH, Cook JR, Sohani AR, et al. Lymphoplasmacytic lymphoma. In : Swerdlow SH, Campo E, Harris NL, editors. World health organization classification of tumour of hematopoietic and lymphoid tissues. Lyon, France: IARC Press;2017. p. 232–235.

2. Kang J, Hong JY, Suh C. Clinical features and survival outcomes of patients with lymphoplasmacytic lymphoma, including non-IgM type, in Korea: a single-center experience. Blood Res. 2018; 53:189–197.

3. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenstrom macroglobulinemia. Blood. 2009; 113:4163–4170.

4. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009; 27:3830–3835.

5. Treon SP, Merlini G, Morra E, Patterson CJ, Stone MJ. Report from the Sixth International Workshop on Waldenström's Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011; 11:68–73.

6. Sekiguchi N, Takezako N, Nagata A, et al. Successful treatment of immunoglobulin D myeloma by bortezomib and dexamethasone therapy. Intern Med. 2011; 50:2653–2657.

7. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003; 30:110–115.

8. Sekiguchi N, Nomoto J, Nagata A, et al. Gene expression profile signature of aggressive Waldenström macroglobulinemia with chromosome 6q deletion. Biomed Res Int. 2018; 2018:6728128.

9. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012; 367:826–833.

10. Cao X, Medeiros LJ, Xia Y, et al. Clinicopathologic features and outcomes of lymphoplasmacytic lymphoma patients with monoclonal IgG or IgA paraprotein expression. Leuk Lymphoma. 2016; 57:1104–1113.

11. King RL, Gonsalves WI, Ansell SM, et al. Lymphoplasmacytic lymphoma with a non-IgM paraprotein shows clinical and pathologic heterogeneity and may harbor MYD88 L265P mutations. Am J Clin Pathol. 2016; 145:843–851.

12. Varettoni M, Boveri E, Zibellini S, et al. Lymphoplasmacytic lymphoma not associated with an IgM monoclonal paraprotein has distinctive clinical and biological features and a similar outcome as compared with Waldenstrom's macroglobulinemia: multicentric study of the rete ematologica lombarda. Blood (ASH Annual Meeting Abstracts). 2017; 130:Suppl. 4045.

13. Itchaki G, Dubeau T, Keezer A, et al. Non-IgM secreting lymphoplasmacytic lymphoma - experience of a reference center for waldenstrom macroglobulinemia. Blood (ASH Annual Meeting Abstracts). 2018; 132:Suppl. 2886.

14. Olszewski AJ, Treon SP, Castillo JJ. Application and outcomes of bendamustine- or bortezomib-based therapy for waldenstrom's macroglobulinemia. Blood (ASH Annual Meeting Abstracts). 2017; 130:Suppl. 348.

15. Sekiguchi N, Hamano A, Kitagawa T, Ito K, Hirano K, Yamada K. What is the most appropriate regimen for untreated Waldenström macroglobulinemia? - An updated analysis of rituximab and half-dose CHOP therapy and cost effectiveness. Blood Res. 2019; 54:153–156.

16. Castillo JJ, Gustine JN, Meid K, et al. Response and survival for primary therapy combination regimens and maintenance rituximab in Waldenström macroglobulinaemia. Br J Haematol. 2018; 181:77–85.